# NephroNovus

**Type:** venture
**Status:** Draft
**Confidence:** Low
**Focus:** chronic kidney disease, renal fibrosis, drug discovery, computational biology, Altitude Lab alumni
**Stage:** Extremely early; founded circa 2023; Altitude Lab alumni per public portfolio
**Location:** Salt Lake City, UT (inferred from Altitude Lab ecosystem; not stated on portfolio listing)
**Updated:** 2026-06-19
**Needs-reviewed:** 2026-06-19
**Hero:** https://picsum.photos/seed/nephronovus-renal-fibrosis-2026/1600/1100
**Pull:** *Father–son drug-discovery bet on reversing renal fibrosis — incubator-validated premise, almost no public pipeline.*
**Relates:** cites [Altitude Lab Portfolio: NephroNovus](nephronovus-altitude-lab-portfolio.md)

## Summary

NephroNovus is a therapeutics company listed on Altitude Lab's portfolio with an estimated **2023** founding year and **Alumni** status. The incubator describes it as exploring biochemical pathways and computational techniques to address **chronic kidney disease**.

An Altitude Lab resident story (April 2025) by co-founder **Kevin Yang** adds narrative detail: NephroNovus grew from years of nephrology lab work with his father (scientific co-founder), aims at **renal fibrosis** as a driver of CKD progression, and blends biochemical discovery with computational methods. Kevin Yang handles business, strategy, and operations; his father leads the scientific foundation.

**What is not publicly disclosed:** lead compounds, mechanism of action, animal data, patents, fundraising amounts, clinical timeline, or team size beyond founder narrative. A company domain (`nephronovus.com`) shows branding only. Legacy intake described a two-person team and pre-seed incubation — portfolio data now shows **Alumni**, which may mean residency ended; current operating intensity is unknown.

## Impact

Chronic kidney disease affects hundreds of millions of people worldwide. Established therapies mostly slow decline; **no widely approved drug reverses established renal fibrosis** at scale. Fibrosis also connects CKD progression to dialysis and transplant burden.

If NephroNovus could safely reverse or materially regress renal fibrosis in humans, the clinical and economic impact would be large. At this evidence level, that remains a **scientific premise**, not a demonstrated company capability. CKD drug discovery is crowded and failure-prone; many antifibrotic approaches have stalled in clinic.

## What They Are Building

Public materials support only a high-level model:

1. **Problem:** Chronic kidney disease progression driven in part by renal fibrosis (scarring).
2. **Approach:** Combine biochemical pathway discovery with computational innovation (exact targets and algorithms undisclosed).
3. **Stage:** Early drug-discovery company; no published results or trial registrations tied to NephroNovus were found in sources captured here.

Do not infer a specific modality (small molecule, biologic, RNA, etc.) from portfolio language alone.

## What They Need Now

Likely needs for a company at this stage include renal fibrosis biology expertise, medicinal chemistry or biologics discovery, computational drug-discovery engineering, preclinical pharmacology, IP counsel, and seed fundraising. A two-founder team (if still accurate) implies high leverage per contributor but also key-person risk.

## Who Could Help

Useful helpers — if the company is actively building — include CKD clinical KOLs, renal fibrosis model CRO partners, computational chemistry advisors, and early biotech investors comfortable with binary preclinical risk. [Altitude Labs](altitude-labs.md) alumni network may remain a connector even after residency ends.

## Utah Context

NephroNovus is part of the Altitude Lab portfolio on Salt Lake City's Recursion-adjacent life-science campus — the same ecosystem as [Evolution Bio](evolution-bio.md), [Sethera Therapeutics](sethera-therapeutics.md), and [CaLycia Biosciences](calycia-biosciences.md). The father–son origin story ties the venture to Utah nephrology research culture, though the specific academic lab affiliation is not documented on the portfolio page itself.

## Evidence

- [Altitude Lab Portfolio: NephroNovus](nephronovus-altitude-lab-portfolio.md)

## See Also

- [Altitude Labs](altitude-labs.md) — Utah health-care incubator that listed NephroNovus
- [Evolution Bio](evolution-bio.md) — another early Altitude Lab–associated Utah platform/discovery company with sparse public disclosure

## Open Questions

- **Pipeline and mechanism** — no public disclosure of targets, hits, or lead series.
- **Funding** — no announced round, grant, or SBIR award verified in sources reviewed.
- **Residency vs. alumni status** — portfolio lists Alumni; confirm whether the company still uses Altitude Lab space or services.
- **Team size and hiring** — legacy intake cited two employees; current headcount unknown.
- **Peer-reviewed validation** — no publications attributing specific NephroNovus assets were captured; distinguish from unrelated CKD antifibrosis academic work in the literature.
- **Competitive landscape** — major pharma and biotech continue CKD/antifibrosis programs with mixed trial history; NephroNovus differentiation is unstated.
- The placeholder hero should be replaced with a cleared scientific or team image when rights are confirmed.